China Approves 117 Video Games Amid Black Myth: Wukong Phenomenon

Saturday, 31 August 2024, 06:41

Black Myth: Wukong mania has led to China approving 117 video games, marking the largest batch in 2024. This surge demonstrates a robust recovery in the gaming market, revitalized by the blockbuster success of Black Myth: Wukong, which quickly gained traction among gamers both domestically and internationally.
South China Morning Post
China Approves 117 Video Games Amid Black Myth: Wukong Phenomenon

China's Gaming Market Surge

This month, China's National Press and Publication Administration (NPPA) unveiled approvals for 117 video games, the highest number so far in 2024, as excitement surrounds the release of Black Myth: Wukong. Tencent Holdings' Yirenzhixia, and titles from NetEase and Alibaba’s Lingxi Games are among the newly licensed games.

Market Rebound and Player Demand

Since halting licensing in April 2022, the NPPA has approved 850 domestic titles in the first eight months of this year, a significant increase from 609 in the same period in 2023. The new approvals reflect a revitalized gaming market fueled by the blockbuster success of Black Myth: Wukong.

  • Black Myth: Wukong, developed by Game Science, is based on the classic novel Journey to the West.
  • The game has sold over 10 million copies in just three days since its release.
  • Available on PlayStation 5, Windows PC, and Steam, with an Xbox release expected.

Bright Future for Chinese Gaming

The impressive sales figures for Black Myth: Wukong point to strong consumer spending trends in China, with Newzoo estimating the gaming market to reach US$45 billion this year.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe